Search results
Added:
3 weeks ago
Added:
1 day ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
Added:
2 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial…
View more
Added:
1 day ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Added:
2 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from…
View more
Added:
2 months ago
Added:
7 months ago
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different…
View more
Added:
2 months ago
Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.ESC Congress 2025 Hot Line Trials Discussed:VICTORVICTORIADIGIT-HFDAPA-ACT-HF-TIMIREBOOT-CNICBETAMI-DANBLOCKREFINE ICDStay tuned for Radcliffe Cardiology’s in-depth…
View more
Added:
2 months ago
Added:
3 months ago